These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 16400826

  • 21. IGF binding protein alterations on periplaque oligodendrocytes in multiple sclerosis: implications for remyelination.
    Wilczak N, Chesik D, Hoekstra D, De Keyser J.
    Neurochem Int; 2008 Jun; 52(8):1431-5. PubMed ID: 18471934
    [Abstract] [Full Text] [Related]

  • 22. Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis?
    Herbeuval JP, Shearer GM.
    AIDS Rev; 2006 Jun; 8(1):3-8. PubMed ID: 16736946
    [Abstract] [Full Text] [Related]

  • 23. An in-vitro approach to the study of oligodendrocytes and their involvement in multiple sclerosis.
    Szuchet S, Dumas M.
    Neurol Clin; 1983 Aug; 1(3):729-55. PubMed ID: 6680171
    [Abstract] [Full Text] [Related]

  • 24. Role for CXCR2 and CXCL1 on glia in multiple sclerosis.
    Omari KM, John G, Lango R, Raine CS.
    Glia; 2006 Jan 01; 53(1):24-31. PubMed ID: 16086366
    [Abstract] [Full Text] [Related]

  • 25. Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis?
    Podbielska M, Hogan EL.
    Mult Scler; 2009 Sep 01; 15(9):1011-29. PubMed ID: 19692432
    [Abstract] [Full Text] [Related]

  • 26. Multiple sclerosis as a disease of immune regulation.
    Waksman BH, Reynolds WE.
    Proc Soc Exp Biol Med; 1984 Mar 01; 175(3):282-94. PubMed ID: 6229799
    [No Abstract] [Full Text] [Related]

  • 27. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 28. Neuropathology in multiple sclerosis: new concepts.
    Lassmann H.
    Mult Scler; 1998 Jun 15; 4(3):93-8. PubMed ID: 9762654
    [Abstract] [Full Text] [Related]

  • 29. [Multiple sclerosis physiopathology].
    Créange A.
    Soins; 2009 Nov 15; (740):32-5. PubMed ID: 20014530
    [No Abstract] [Full Text] [Related]

  • 30. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.
    van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, Serrano L, Quax WJ.
    Proc Natl Acad Sci U S A; 2006 Jun 06; 103(23):8634-9. PubMed ID: 16731632
    [Abstract] [Full Text] [Related]

  • 31. [Immunological abnormalities in multiple sclerosis].
    Tabira T.
    No To Shinkei; 1983 Jun 06; 35(6):535-41. PubMed ID: 6194805
    [No Abstract] [Full Text] [Related]

  • 32. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, Kleibeuker JH, Koornstra JJ.
    J Clin Oncol; 2006 Nov 01; 24(31):4998-5004. PubMed ID: 17075118
    [Abstract] [Full Text] [Related]

  • 33. The role of immune system cells in multiple sclerosis.
    Compr Ther; 1990 Dec 01; 16(12):67. PubMed ID: 2076604
    [No Abstract] [Full Text] [Related]

  • 34. The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease.
    Brunetti G, Colucci S, Rizzi R, Mori G, Colaianni G, Oranger A, Zallone A, Liso V, Grano M.
    Ann N Y Acad Sci; 2006 Apr 01; 1068():334-40. PubMed ID: 16831934
    [Abstract] [Full Text] [Related]

  • 35. Absence of cross-reactive antibodies to myelin and viral antigens in multiple sclerosis.
    Bernard CC, Townsend E.
    Prog Clin Biol Res; 1984 Apr 01; 146():215-22. PubMed ID: 6201892
    [No Abstract] [Full Text] [Related]

  • 36. See no evil, hear no evil, do no evil: the lessons of immune privilege.
    Niederkorn JY.
    Nat Immunol; 2006 Apr 01; 7(4):354-9. PubMed ID: 16550198
    [Abstract] [Full Text] [Related]

  • 37. Apoptosis in multiple sclerosis.
    Zipp F.
    Cell Tissue Res; 2000 Jul 01; 301(1):163-71. PubMed ID: 10928289
    [Abstract] [Full Text] [Related]

  • 38. The molecular perspective: tumor necrosis factor.
    Goodsell DS.
    Oncologist; 2006 Jan 01; 11(1):83-4. PubMed ID: 16401717
    [No Abstract] [Full Text] [Related]

  • 39. Long lasting heat shock stimulation of TRAIL-induced apoptosis in transformed T lymphocytes.
    Moulin M, Arrigo AP.
    Exp Cell Res; 2006 Jun 10; 312(10):1765-84. PubMed ID: 16584728
    [Abstract] [Full Text] [Related]

  • 40. Multiple sclerosis: oligodendrocytes in active lesions do not express class II major histocompatibility complex molecules.
    Lee SC, Raine CS.
    J Neuroimmunol; 1989 Dec 10; 25(2-3):261-6. PubMed ID: 2479662
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.